Crinetics Pharmaceuticals Appoints New CMO and CSO
Ticker: CRNX · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $200 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change, board-of-directors
Related Tickers: CRNX
TL;DR
CRNX brings in new CMO & CSO, Levitt also joins board.
AI Summary
Crinetics Pharmaceuticals, Inc. announced on October 10, 2024, the appointment of Dr. Michael R. Levitt as Chief Medical Officer and Dr. David M. Recker as Chief Scientific Officer. The company also reported the election of Dr. Levitt to its Board of Directors. These appointments are effective immediately.
Why It Matters
The appointment of experienced executives like a new Chief Medical Officer and Chief Scientific Officer can signal a strategic shift or acceleration in the company's drug development pipeline.
Risk Assessment
Risk Level: medium — Key executive appointments can impact a company's strategic direction and operational execution, carrying inherent risks.
Key Players & Entities
- Crinetics Pharmaceuticals, Inc. (company) — Registrant
- Dr. Michael R. Levitt (person) — Appointed Chief Medical Officer and elected to Board of Directors
- Dr. David M. Recker (person) — Appointed Chief Scientific Officer
- October 10, 2024 (date) — Effective date of appointments
FAQ
Who has been appointed as the new Chief Medical Officer of Crinetics Pharmaceuticals?
Dr. Michael R. Levitt has been appointed as the new Chief Medical Officer.
What other role has Dr. Michael R. Levitt taken on?
Dr. Michael R. Levitt has also been elected to the Board of Directors of Crinetics Pharmaceuticals.
Who is the new Chief Scientific Officer?
Dr. David M. Recker has been appointed as the new Chief Scientific Officer.
When were these appointments effective?
The appointments were effective as of October 10, 2024.
What is the principal executive office address for Crinetics Pharmaceuticals?
The principal executive office is located at 6055 Lusk Boulevard, San Diego, California, 92121.
Filing Stats: 714 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-10-16 16:08:00
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select
- $200 — r. Hassard will receive compensation of $200 per hour as well as reimbursement for r
Filing Documents
- d850938d8k.htm (8-K) — 26KB
- d850938dex101.htm (EX-10.1) — 53KB
- d850938dex102.htm (EX-10.2) — 55KB
- 0001193125-24-238120.txt ( ) — 283KB
- crnx-20241010.xsd (EX-101.SCH) — 3KB
- crnx-20241010_lab.xml (EX-101.LAB) — 17KB
- crnx-20241010_pre.xml (EX-101.PRE) — 11KB
- d850938d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Consulting Agreement, effective as of October 15, 2024, between Crinetics Pharmaceuticals, Inc. and James Hassard. 10.2 Separation and Release Agreement, dated October 10, 2024, between Crinetics Pharmaceuticals, Inc. and James Hassard. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: October 16, 2024 By: /s/ R. Scott Struthers, Ph.D. R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)